Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company.
A number of analysts recently issued reports on BAYRY shares. Zacks Research raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 10th. DZ Bank upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a "hold" rating in a report on Friday, May 29th.
Get Our Latest Report on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Stock Performance
OTCMKTS:BAYRY opened at $13.60 on Thursday. Bayer Aktiengesellschaft has a twelve month low of $7.19 and a twelve month high of $15.23. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The company has a 50-day moving average of $11.72 and a 200-day moving average of $11.86. The firm has a market cap of $53.45 billion, a price-to-earnings ratio of -21.25, a price-to-earnings-growth ratio of 4.48 and a beta of 0.55.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The business had revenue of $15.73 billion during the quarter, compared to analysts' expectations of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts forecast that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.
In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
